-
Let life-saving drugs no longer be in short supply-the construction of a centralized production base for the drug consortium ensures the supply of small varieties of drugs
Time of Update: 2021-04-22
The reporter learned that in order to effectively protect patients' medication and solve their problems, in recent years, the Ministry of Industry and Information Technology, in conjunction with relevant departments, has continued to guide enterprises to build production bases for small varieties of drugs (drugs in short supply), and in-depth development of supply-side structural reforms in the pharmaceutical industry.
-
The disease control rate exceeds 95%!
Time of Update: 2021-04-19
SourceGuanlan PharmaceuticalOn March 29, Yingli Pharmaceuticals announced that its PI3Kδ inhibitor linperlisib (YY-20394) for the treatment of relapsed/refractory follicular lymphoma phase 2 registration clinical trial was initially completed.
-
Hengrui Pharmaceuticals ERK Inhibitor Approved for Clinical
Time of Update: 2021-04-19
On March 26, the CDE official website showed that Hengrui's application for clinical trial of extracellular regulatory protein kinase (ERK) inhibitors has been approved by the State Food and Drug Administration by default.
The MAPK signaling pathway is transmitted to multiple targets in the cell via RAS-RAF-MEK-ERK.
-
Health yuan hits new inhaler medicine again!
Time of Update: 2021-04-19
Figure 1: Healthyuan’s application status of aclidinium bromide inhalation powderSource: CDE official websiteTable 1: The status of key inhalant products declared by Joincare and its subsidiaries earlierSource: Meinenet MED2.
In addition, the clinical application of category 3 imitation of mometasone formoterol inhalation aerosol is under review and approval.
-
The national pharmacy renovation begins!
Time of Update: 2021-04-19
Sorting out: XiyuAttention pharmacies that sell medical masks, condoms, and sticky medical devices, the nationwide inspection is coming. 590,000 medical equipment operating companies, the nationwide i
-
Overview of the U.S. Biosimilar Drug Market 2020
Time of Update: 2021-04-19
S. dollars)In 2020, the overall price of Humira in the US market has increased by about 8% compared to the previous year, and the share of sales in the total global revenue continues to rise to 81.
-
The results of the fourth batch of national procurement, 4 provinces clarify the landing time
Time of Update: 2021-04-19
Jiangsu On March 19, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fourth Batch of State-Organized Drug Centralized Procurement Results", which officially determined the launch time of the fourth batch of nationally selected results in Jiangsu Province.
-
Up to about 1.08 billion yuan, Fuhong Henlius won the right of a BRAF inhibitor from Runxin Biotech
Time of Update: 2021-04-19
Source: Immediate Medicine NewsOn March 29, 2021, Henlius Fuhong announced that it has reached an exclusive license cooperation with Runxin Bio for the BRAF V600E inhibitor RX208.
-
Sell 16.8 billion to a new high!
Time of Update: 2021-04-19
Table 2: The current situation of obtaining production licenses for Chinese traditional medicines in various regionsSource: company annual report, *is newly added last yearAs the company’s newly established integrated business enterprises actively promote production capacity, the obtained TCM formula granule extraction and preparation production licenses have increased significantly compared with the same period last year.
-
GlaxoSmithKline Benlysta (belyumumab) is recommended and approved by the EU CHMP
Time of Update: 2021-04-19
GlaxoSmithKline (GSK) recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting the approval of Benlysta (Chinese trade name: Beliteng, generic name: belimumab, Belyumumab) intravenous and subcutaneous preparations, combined with background immunosuppressive therapy, are used to treat adult patients with active lupus nephritis (LN).
-
Gilead's first TROP-2 target drug Trodelvy enters EU review
Time of Update: 2021-04-19
Gilead recently announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for the targeted anticancer drug Trodelvy (sacituzumab govitecan-hziy, SG), which is used for treatment: previously accepted At least two therapies, at least one of which treats unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) adult patients with locally advanced or metastatic disease.
-
China Resources Double Crane: China Resources Secco Finasteride Tablets (1mg) Approved for Listing
Time of Update: 2021-04-19
It is reported that China Resources SECCO has invested RMB 3.
China Resources Secco Finasteride (5mg) is mainly used for the treatment of benign prostatic hyperplasia (BPH) with existing symptoms and passed the consistency evaluation on September 18, 2019.
-
Pfizer announces Phase 3 clinical results of abrocitinib, a new-generation oral JAK1 inhibitor
Time of Update: 2021-04-19
(100mg, 200mg, once a day, orally), positive control drug dupilumab (300mg, baseline 600mg loading dose, once every 2 weeks, subcutaneous injection), placebo efficacy and safety, all patients received topical therapy.
-
The most comprehensive analysis of formula particles: policy, market, competing products, marketing...
Time of Update: 2021-04-19
According to the "Blue Book on the Development of Chinese Medicine Decoction Pieces Industry", the market size of Chinese medicine prescription granules has increased from 2 billion yuan in 2010 to 15 billion yuan in 2018, with a compound growth rate of 28.
-
The domestic pharmaceutical packaging material industry, which is constantly catching up and upgrading from bottle cap to bottle body, has a promising future
Time of Update: 2021-04-19
Previously, according to information disclosed by the China Vaccine Industry Association, there are currently more than 60 domestic manufacturers of relevant pharmaceutical packaging materials.
-
Johnson & Johnson's S1P1 regulator Ponvory (ponesimod) is about to be approved in the EU
Time of Update: 2021-04-19
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (JNJ), recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting approval of Ponvory (ponesimod), which is a once-daily, orally administered drug , Selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease determined by clinical or imaging features.
-
$470.5 million!
Time of Update: 2021-04-19
▲The mechanism of action of anti-CD47 antibody (picture source: "Nature Biomedical Engineering")Reference materials:[1] ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China.
Retrieved 2021-03-31, from 3d-medicines-signed-exclusive-license-agreement-to-develop-manufacture-and-commercialize-imc-002-in-greater-china-301258121.
-
Nearly half of the products are exempt from clinical evaluation!
Time of Update: 2021-04-19
Medical Network, March 29, March 26, the "Regular Policy Briefing of the State Council" explained the relevant situation of the "Regulations on the Supervision and Administration of Medical Devices"
-
Tide Pharmaceuticals was commended by the National Chamber of Commerce and Industry of the Pharmaceutical Industry
Time of Update: 2021-04-19
has won two honors, the "Development Contribution Award" of the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce and the 2020 "Star Vice President Unit".
-
Johnson & Johnson scrapped 15 million doses of new crown vaccine due to confusion and errors in the production process
Time of Update: 2021-04-19
According to overseas media reports on March 31, 15 million doses of Johnson & Johnson vaccine were scrapped due to production errors in the vaccine factory.
